Cancer Immunology and Immunotherapy

The recent FDA approvals of Provenge� as the first therapeutic cancer vaccine and Ipilimumab� as the first monoclonal antibody that blocks negative immune regulation are landmark achievements that highlight substantive progress in cancer immunology. These novel treatments derive from the cumulative insights of basic and translational scientists into the mechanisms of protective tumor immunity in cancer patients. Advances in genetic, cellular, and biochemical technologies have dramatically increased our understanding of the pathways through which the host responds to cancer. Tumor-host interactions in the microenvironment are increasingly recognized to play a critical role in determining disease inhibition or promotion. This Keystone Symposia meeting will bring together leading cancer immunologists to discuss their most recent insights into immune recognition, regulation, tumor escape, and therapeutic manipulation. Emerging areas of cancer metabolism and material science engineering that relate to cancer immunology will be highlighted. The integration of basic and clinical aspects of tumor immunity in this meeting should stimulate interest from a wide array of investigators and students. The concurrent meeting on Antibodies as Drugs will underscore the increasing connections between these fields, and potentially accelerate the development of new cancer immunotherapies.
+ show speakers and program
SUNDAY, JANUARY 27

15:00—19:30
Arrival and Registration

18:15—19:15
Refreshments


Following Session is for Antibodies as Drugs (J3)

19:15—20:30
Welcome and Keynote Address
Registered attendees can view abstracts starting on 12/27/2012

Jeffrey V. Ravetch, Rockefeller University, USA
Remodeling Antibody Glycans for Immunomodulation

19:15—20:30
Welcome and Keynote Address
Registered attendees can view abstracts starting on 12/27/2012

James P. Allison, Memorial Sloan-Kettering Cancer Center, USA
Checkpoint Blockade


MONDAY, JANUARY 28

07:00—08:00
Breakfast

08:00—11:00
Tumor Targeting - From Understanding Mechanisms to New Targeting Agents (Joint)
Registered attendees can view abstracts starting on 12/27/2012

Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Synergistic Antibody and Cytokine Effects in Cancer Immunotherapy

Kerry Chester, University College London Cancer Institute, UK
Antibody-Targeted Iron Oxide Nanoparticles for Cancer

Dario Neri, ETH Zürich, Switzerland
Armed Antibodies for Vascular Targeting

Anna M. Wu, University of California, Los Angeles, USA
Engineered Antibodies for Molecular Imaging of Cancer

Short Talk(s) Chosen from Abstracts

09:20—09:40
Coffee Break

11:00—13:00
Poster Setup

13:00—22:00
Poster Viewing


On Own for Lunch and Recreation


Following Session is for Antibodies as Drugs (J3)

14:30—16:30
Workshop 1: Emerging Antibody Generation Methods

Short Talks Chosen from Abstracts

16:30—17:00
Coffee Available


Following Session is for Antibodies as Drugs (J3)

17:00—19:00
Payloaded Antibodies for Cancer Treatment
Registered attendees can view abstracts starting on 12/27/2012

Peter D. Senter, Seattle Genetics Inc., USA
Antibody-Drug Conjugates with Auristatins: From ADC Optimization to a Clinically Approved Drug and Beyond

Speaker to be Announced

Paul G. Polakis, Genentech, Inc., USA
Target Selection for Antibody-Drug Conjugates

Short Talk Chosen from Abstracts

17:00—19:00
Tumor Microenvironment
Registered attendees can view abstracts starting on 12/27/2012

Wolf-Herman Fridman, Hôpital Européen Georges-Pompidou, France
The Immune Microenvironment of Primary and Metastatic Human Tumors

Robert D. Schreiber, Washington University School of Medicine, USA
Cancer Immunoediting Mechanisms and Therapeutic Opportunities

Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Inflammation and Cancer

Short Talk Chosen from Abstracts

19:00—20:00
Social Hour w/ Lite Bites

19:30—22:00
Poster Session 1


TUESDAY, JANUARY 29

07:00—08:00
Breakfast


Following Session is for Antibodies as Drugs (J3)

08:00—11:00
Antibodies in Infectious Diseases
Registered attendees can view abstracts starting on 12/27/2012

Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Human Antibodies to Infectious Disease Targets

Dennis R. Burton, The Scripps Research Institute, USA
HIV Reverse Vaccinology

Gary J. Nabel, NIAID, National Institutes of Health, USA
Broadly Neutralizing Antibodies to HIV

Erica Ollmann Saphire, The Scripps Research Institute, USA
Antibodies Against Ebola

Short Talk(s) Chosen from Abstracts

08:00—11:00
Engineering and Immunotherapy
Registered attendees can view abstracts starting on 12/27/2012

David J. Mooney, Harvard University, USA
Polymer Scaffolds for Immunotherapy

Darrell J. Irvine, Massachusetts Institute of Technology, USA
Nanoparticles for Cellular Therapy

Carl H. June, University of Pennsylvania, USA
Engineered T Cells for Adoptive Therapy

Laurence J.N. Cooper, University of Texas MD Anderson Cancer Center, USA
Sleeping Beauty Transposase for Engineered T Cells

Short Talk(s) Chosen from Abstracts

09:20—09:40
Coffee Break

11:00—13:00
Poster Setup

13:00—22:00
Poster Viewing


On Own for Lunch and Recreation

16:30—17:00
Coffee Available


Following Session is for Antibodies as Drugs (J3)

17:00—19:00
New Technologies for Generating Proteins with Novel Functions
Registered attendees can view abstracts starting on 12/27/2012

David Baker, University of Washington, USA
Computational Design/Redesign of Proteins

George M. Church†, Harvard Medical School, USA
A Logic-Gated Nanorobot for Targeted Transport of Molecular Payloads

Julia Shifman, Hebrew University of Jerusalem, Israel
Computational Design of Protein-Protein Interactions

Short Talk Chosen from Abstracts

17:00—19:00
Cancer Vaccines
Registered attendees can view abstracts starting on 12/27/2012

Cornelis J. M. Melief, Leiden University Medical Center, Netherlands
Long Peptides

Cornelia L. Trimble, Johns Hopkins University School of Medicine, USA
Talk Title to be Determined

David H. Kirn, Jennerex, USA
Systemic Oncolytic Immunotherapy with Cancer-Targeted Vaccinia Virus JX-594: Clinical Proof-of-Concept and Product Approval Path

Short Talk Chosen from Abstracts

19:00—20:00
Social Hour w/ Lite Bites

19:30—22:00
Poster Session 2


WEDNESDAY, JANUARY 30

07:00—08:00
Breakfast


Following Session is for Antibodies as Drugs (J3)

08:00—11:00
Bispecific and Multispecific Targeting Agents
Registered attendees can view abstracts starting on 12/27/2012

Carlos F. Barbas III, The Scripps Research Institute, USA
Multifunctional and Multi-Specific Antibodies: New Strategies and Activities

Kaspar H. Binz, Molecular Partners, Switzerland
Exploiting Novel Therapeutic Mechanisms Using Multi-Specific DARPins

James D. Marks, University of California, San Francisco, USA
Antibody Combinations for Treatment of Botulism

Lutz Jermutus, MedImmune Ltd, UK
Bispecific Antibodies from Phenotypic Selections Targeting Pseudomonas aeruginosa

Short Talk(s) Chosen from Abstracts

08:00—11:00
Adoptive Cellular Therapy
Registered attendees can view abstracts starting on 12/27/2012

Stanley R. Riddell, Fred Hutchinson Cancer Research Center, USA
T Cell Subsets in Adoptive Therapy

Nicholas P. Restifo, NCI, National Institutes of Health, USA
Self-Renewal and Persistence of T Cell Subsets

Catherine M. Bollard, Baylor College of Medicine, USA
Adoptive T Cell Therapy - Moving Beyond Phase I Studies

Robert S. Negrin, Stanford University, USA
Allogenic Bone Marrow Transplantation

Short Talk(s) Chosen from Abstracts

09:20—09:40
Coffee Break

11:00—13:00
Poster Setup

13:00—22:00
Poster Viewing


On Own for Lunch and Recreation


Following Session is for Antibodies as Drugs (J3)

14:30—16:30
Workshop 2: Enhancing Effector Functions and Extending Half-Life

Short Talks Chosen from Abstracts

16:30—17:00
Coffee Available


Following Session is for Antibodies as Drugs (J3)

17:00—19:00
Modulating the Activity of Growth Factor Receptors
Registered attendees can view abstracts starting on 12/27/2012

Andreas G. Plückthun, University of Zürich, Switzerland
New Approaches to Receptor Antagonism

Ermanno Gherardi, University of Pavia, UK
Met Biology and Structural Biochemistry

Speaker to be Announced

Short Talk Chosen from Abstracts

17:00—19:00
Metabolism and Cancer
Registered attendees can view abstracts starting on 12/27/2012

Laurence Zitvogel, Institut Gustave Roussy, France
ATP and Tumor Cell Immunogenicity

Vincenzo Bronte, University of Verona, Italy
Myeloid Suppressive Mechanisms

George C. Prendergast, Lankenau Institute for Medical Research, USA
IDO/IDO2 Genetics and Therapeutic Correction of the IDO Pathway

Short Talk Chosen from Abstracts

19:00—20:00
Social Hour w/ Lite Bites

19:30—22:00
Poster Session 3


THURSDAY, JANUARY 31

07:00—08:00
Breakfast

08:00—11:00
Immunomodulatory Antibody Therapies (Joint)
Registered attendees can view abstracts starting on 12/27/2012

Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
PD-1 Blockade in Cancer Therapy

Nils Lonberg, Bristol-Myers Squibb, USA
Development Hurdles for Immuno-Oncology Antibody Drugs

Patrick A. Baeuerle, Micromet GmbH, Germany
Cancer Therapy by Bispecific, T Cell-Engaging Antibodies

Bent Jakobsen, Immunocore Ltd, UK
IMCgp100: A Bispecific TCR Anti-CD3 Fusion for the Treatment of Malignant Melanoma

Short Talk(s) Chosen from Abstracts

Short Talk(s) Chosen from Abstracts

09:00—09:20
Coffee Break


On Own for Lunch and Recreation

16:30—17:00
Coffee Available


Following Session is for Antibodies as Drugs (J3)

17:00—19:00
Challenges and New Opportunities with Antibody Drugs
Registered attendees can view abstracts starting on 12/27/2012

Ryan J. Watts, Genentech, Inc., USA
Bispecific Antibodies to Deliver Therapeutics across the Blood-Brain Barrier

Leo James, University of Cambridge, UK
Intracellular Immunity and TRIM21

Erkki Ruoslahti, Sanford-Burnham Medical Research Institute, USA
Increasing Extravasation with Peptides

Short Talk Chosen from Abstracts

17:00—19:00
Anti-Cancer Antibodies
Registered attendees can view abstracts starting on 12/27/2012

George J. Weiner, University of Iowa, USA
Therapeutic Mechanisms of Monoclonal Antibodies

Mark J. Smyth, Peter MacCallum Cancer Centre, Australia
Monoclonal Antibody-Based Combinatorial Therapies

Glenn Dranoff, Dana-Farber Cancer Institute, USA
Therapy-Induced Antibody Responses

Short Talk Chosen from Abstracts

19:00—20:00
Social Hour w/ Lite Bites

20:00—23:00
Entertainment


FRIDAY, FEBRUARY 1


Departure


*Session Chair †Speaker invited, not yet responded.

27 Jan - 1 Feb 2013
Vancouver
Canada
meeting website